PHIO Phio Pharmaceuticals Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1533040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-84.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-159.0%
ROA-128.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $4.62M | $3.64M | $6.33M | $7.01M | $8.89M |
| SG&A expense | $4.60M | $3.74M | $4.37M | $4.45M | $4.62M |
| Operating income | -$9.22M | -$7.39M | -$10.82M | -$11.46M | -$13.51M |
| Pretax income | — | — | — | -$11.48M | -$13.29M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | -$13.29M |
| EBITDA | -$9.22M | -$7.38M | -$10.77M | -$11.39M | -$13.44M |
| EPS (basic) | -1.45 | -9.08 | -46.76 | -10.10 | -12.43 |
| EPS (diluted) | — | -9.08 | -46.76 | -10.10 | -12.43 |
| Weighted avg. shares (diluted) | — | 787,466 | 231,508 | 1.14M | 1.07M |
| Banking | |||||
| Net interest income | — | $231,000 | -$8,000 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $21.03M | $5.38M | $8.49M | $11.83M | $24.11M |
| Current assets | $21.48M | $5.74M | $9.32M | $12.45M | $24.73M |
| PP&E, net | $11,000 | $2,000 | $6,000 | $183,000 | $133,000 |
| Total assets | $21.49M | $5.74M | $9.36M | $12.81M | $25.17M |
| Current liabilities | — | $1.01M | $1.63M | $1.94M | $3.07M |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $1.34M | $1.01M | $1.63M | $1.97M | $3.24M |
| Shareholders' equity | $20.15M | $4.72M | $7.73M | $10.84M | $21.93M |
| Net debt | — | — | — | — | -$24.11M |
| Shares outstanding | 11.62M | 1.73M | 416,368 | 1.14M | 1.13M |
| Cash flow statement | |||||
| Operating cash flow | -$7.98M | -$7.11M | -$10.75M | -$12.13M | -$11.86M |
| Capital expenditure | $12,000 | $1,000 | $5,000 | $121,000 | $51,000 |
| Free cash flow | -$7.99M | -$7.11M | -$10.75M | -$12.25M | -$11.91M |
| Investing cash flow | -$12,000 | $8,000 | -$5,000 | -$121,000 | -$51,000 |
| Financing cash flow | $23.64M | $4.00M | $7.41M | -$26,000 | $21.72M |
| Depreciation & amortization | $3,000 | $2,000 | $56,000 | $71,000 | $75,000 |
| Stock-based compensation | $481,000 | $147,000 | $303,000 | $414,000 | $480,000 |
Free plan shows the latest 5 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.